Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable thoracic esophageal squamous cell carcinoma
ChiCTR2100049245Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Aug 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab, paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Pathologic complete response. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
camrelizumabpaclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100049245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049245.